NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) will present at the 13(th) Annual Needham Healthcare Conference in New York on Tuesday, April 8, 2014 at 8:00 a.m. ET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) shares after opening at $28.44 moved to $28.44 on last trade day and at the end of the day closed at $26.49. Company price to sales ratio in past twelve months was calculated as 17.50 and price to cash ratio as 15.09. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) showed a negative weekly performance of 6.30%.
InterMune, Inc. (NASDAQ:ITMN) on Mar. 13 announced that it has agreed to sell 7,500,000 shares of its common stock at a price to the public of $32.75 per share in an underwritten public offering. InterMune estimates net proceeds from the offering to be approximately $233.0 million. InterMune intends to use the net proceeds from the offering to fund the commercialization activities in anticipation of the potential commercial launch of Esbriet in the United States and ongoing commercialization in Europe, to fund research and development programs with Esbriet and other compounds intended to address idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, and for general corporate purposes. InterMune Inc (NASDAQ:ITMN) shares fell 5.50% in last trading session and ended the day on $30.60. InterMune Inc (NASDAQ:ITMN) return on equity ratio is recorded as -164.60% and its return on assets is -48.20%. InterMune Inc (NASDAQ:ITMN) yearly performance is 243.05%.
Macquarie upgraded shares of Illumina (NASDAQ:ILMN) from a neutral rating to an outperform rating in a research note issued to investors on Wednesday, TheFlyOnTheWall.com reports. The firm currently has $170.00 price target on the stock, up from their previous price target of $125.00. Illumina, Inc. (NASDAQ:ILMN) shares moved down 6.65% in last trading session and was closed at $138.57, while trading in range of $ 135.30 – 151.40. Illumina, Inc. (NASDAQ:ILMN) year to date (YTD) performance is 25.30%.
Research analysts at JMP Securities cut their target price on shares of Horizon Pharma (NASDAQ:HZNP) from $22.00 to $21.00 in a report released on Friday, ARN reports. The firm currently has an “outperform” rating on the stock. JMP Securities’ target price indicates a potential upside of 38.89% from the company’s current price. Horizon Pharma Inc (NASDAQ:HZNP) weekly performance is -4.59%. On last trading day company shares ended up $14.13. Horizon Pharma Inc (NASDAQ:HZNP) distance from 50-day simple moving average (SMA50) is -14.28%. Analysts mean target Price for the company is $20.80.